Bliss GVS Pharma Ltd (BLISSGVS) — shareholding pattern, promoter holding, financials and share price
About Bliss GVS Pharma Ltd (BLISSGVS)
Bliss GVS Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BLISSGVS and on the BSE under scrip code 506197. Its ISIN is INE416D01022.
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries.
The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa.
Listed peers in Pharmaceuticals: Aarti Pharmalabs Ltd, Innova Captab Ltd, Orchid Pharma Ltd, IOL Chemicals & Pharmaceuticals Ltd, Zota Health Care Ltd, RPG Life Sciences Ltd.
Valuation & Returns
10 Jul 2026At ₹522 a share on 10 Jul 2026, Bliss GVS Pharma Ltd (BLISSGVS) was valued at a price-to-earnings ratio of 41.09x against an industry P/E of 36.41x and a price-to-book of 5.27x on a book value of ₹99.04 per share as of Mar 2025. Solomo computes return on equity of 12.83% and return on capital employed of 17.71% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 41.09x
- Industry P/E
- 36.41x
- P/B
- 5.27x
- EPS (TTM)
- ₹12.7
- Book value / share
- ₹99.04
- ROE
- 12.83%
- ROCE
- 17.71%
- ROA
- 10.36%
- Debt / equity
- 0.08x
- Dividend yield
- 0.38%
- EBITDA margin
- 25.36%
- 52-week range
- ₹118.35 – ₹552.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Bliss GVS Pharma Ltd (BLISSGVS) reported revenue of ₹927 crore, net profit of ₹135 crore and earnings per share of ₹12.21. That compares with revenue of ₹810 crore and net profit of ₹90 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹257 crore and net profit ₹37 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 747 | 752 | 770 | 810 | 927 |
| Net profit (₹ cr) | 23 | 77 | 82 | 90 | 135 |
| EPS (₹) | 1.45 | 6.8 | 7.21 | 8 | 12.21 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.50% | 9.41% | 6.84% | 14.50% |
| Profit growth | 5.64% | 7.49% | 4.26% | 49.27% |
| Stock price CAGR | 17% | 35% | 71% | 219% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 35.01% of Bliss GVS Pharma Ltd (BLISSGVS) (down 0.35 pp QoQ), foreign institutional investors (FII) hold 8.07% and domestic institutional investors (DII) hold 9.47%. Market capitalisation was ₹5,536 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: GULBARGA TRADING AND INVESTMENT PRIVATE 5.5%, ARJUN GAUTAM ASHRA . 4.76%, CLARUS CAPITAL I 3.51%, LIFE INSURANCE CORPORATION OF INDIA 3.24%, GAUTAM RASIKLAL ASHRA 2.81%, INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS 2.48%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 35.01% | - | 8.07% | 9.47% | 64.99% |
| Mar 2026 | 35.36% | - | 10.45% | 5.04% | 64.64% |
| Dec 2025 | 35.36% | - | 14.54% | 5.78% | 64.64% |
| Sep 2025 | 35.39% | - | 13.27% | 5.98% | 64.61% |
| Jun 2025 | 35.44% | - | 12.65% | 6.54% | 64.56% |
| Mar 2025 | 35.29% | - | 13.18% | 6.55% | 64.71% |
| Dec 2024 | 35.1% | - | 13.51% | 6.55% | 64.9% |
| Sep 2024 | 34.82% | - | 12.13% | 6.57% | 65.18% |